163 related articles for article (PubMed ID: 36216481)
1. Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor-Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen-Targeting Small Interfering RNA.
Ranasinghe P; Addison ML; Webb DJ
J Am Heart Assoc; 2022 Oct; 11(20):e027694. PubMed ID: 36216481
[No Abstract] [Full Text] [Related]
2. Conventional Vasopressor and Vasopressor-Sparing Strategies to Counteract the Blood Pressure-Lowering Effect of Small Interfering RNA Targeting Angiotensinogen.
Uijl E; Ye D; Ren L; Mirabito Colafella KM; van Veghel R; Garrelds IM; Lu HS; Daugherty A; Hoorn EJ; Nioi P; Foster D; Danser AHJ
J Am Heart Assoc; 2022 Aug; 11(15):e026426. PubMed ID: 35876413
[TBL] [Abstract][Full Text] [Related]
3. Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR.
Ye D; Cruz-López EO; Veghel RV; Garrelds IM; Kasper A; Wassarman K; Tu HC; Zlatev I; Danser AHJ
Hypertension; 2024 Jul; 81(7):1491-1499. PubMed ID: 38690653
[TBL] [Abstract][Full Text] [Related]
4. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.
Uijl E; Mirabito Colafella KM; Sun Y; Ren L; van Veghel R; Garrelds IM; de Vries R; Poglitsch M; Zlatev I; Kim JB; Hoorn EJ; Foster D; Danser AHJ
Hypertension; 2019 Jun; 73(6):1249-1257. PubMed ID: 31030610
[TBL] [Abstract][Full Text] [Related]
5. Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension.
Addison ML; Ranasinghe P; Webb DJ
Expert Rev Clin Pharmacol; 2023; 16(11):1025-1033. PubMed ID: 37897397
[TBL] [Abstract][Full Text] [Related]
6. Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics.
Addison ML; Ranasinghe P; Webb DJ
Hypertension; 2023 Nov; 80(11):2243-2254. PubMed ID: 37706295
[TBL] [Abstract][Full Text] [Related]
7. RNA interference treatment targeting angiotensinogen lowers blood pressure.
Carvalho T
Nat Med; 2023 Dec; 29(12):2962-2963. PubMed ID: 37845541
[No Abstract] [Full Text] [Related]
8. Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension.
Olearczyk J; Gao S; Eybye M; Yendluri S; Andrews L; Bartz S; Cully D; Tadin-Strapps M
Hypertens Res; 2014 May; 37(5):405-12. PubMed ID: 24335718
[TBL] [Abstract][Full Text] [Related]
9. Targeting angiotensinogen with RNA-based therapeutics.
Ren L; Colafella KMM; Bovée DM; Uijl E; Danser AHJ
Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):180-189. PubMed ID: 31895165
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats.
Tamura K; Umemura S; Nyui N; Yamakawa T; Yamaguchi S; Ishigami T; Tanaka S; Tanimoto K; Takagi N; Sekihara H; Murakami K; Ishii M
Hypertension; 1996 Jun; 27(6):1216-23. PubMed ID: 8641727
[TBL] [Abstract][Full Text] [Related]
11. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats.
Makino N; Sugano M; Ohtsuka S; Sawada S
Hypertension; 1998 May; 31(5):1166-70. PubMed ID: 9576130
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats.
Yuan LF; Sheng J; Lu P; Wang YQ; Jin T; Du Q
Mol Med Rep; 2015 Sep; 12(3):4657-4663. PubMed ID: 26062941
[TBL] [Abstract][Full Text] [Related]
13. Effect of chromosome 19 transfer on blood pressure in the spontaneously hypertensive rat.
St Lezin E; Zhang L; Yang Y; Wang JM; Wang N; Qi N; Steadman JS; Liu W; Kren V; Zidek V; Krenova D; Churchill PC; Churchill MC; Pravenec M
Hypertension; 1999 Jan; 33(1 Pt 2):256-60. PubMed ID: 9931113
[TBL] [Abstract][Full Text] [Related]
14. siRNA takes a jab at hypertension.
Wulczyn KE; Rhee EP
Med; 2024 May; 5(5):383-385. PubMed ID: 38733971
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.
Wu CH; Wang Y; Ma M; Mullick AE; Crooke RM; Graham MJ; Daugherty A; Lu HS
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30530571
[TBL] [Abstract][Full Text] [Related]
16. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen.
Tomita N; Morishita R; Higaki J; Aoki M; Nakamura Y; Mikami H; Fukamizu A; Murakami K; Kaneda Y; Ogihara T
Hypertension; 1995 Jul; 26(1):131-6. PubMed ID: 7541778
[TBL] [Abstract][Full Text] [Related]
17. RNA silencing targeting PIN (protein inhibitor of neuronal nitric oxide synthase) attenuates the development of hypertension in young spontaneously hypertensive rats.
Wang SC; Lin KM; Chien SJ; Huang LT; Hsu CN; Tain YL
J Am Soc Hypertens; 2014 Jan; 8(1):5-13. PubMed ID: 24035314
[TBL] [Abstract][Full Text] [Related]
18. Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia.
Arnold AS; Tang YL; Qian K; Shen L; Valencia V; Phillips MI; Zhang YC
J Hypertens; 2007 Jan; 25(1):197-205. PubMed ID: 17143192
[TBL] [Abstract][Full Text] [Related]
19. Tissue angiotensinogen gene expression induced by lipopolysaccharide in hypertensive rats.
Nyui N; Tamura K; Yamaguchi S; Nakamaru M; Ishigami T; Yabana M; Kihara M; Ochiai H; Miyazaki N; Umemura S; Ishii M
Hypertension; 1997 Oct; 30(4):859-67. PubMed ID: 9336385
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the role of angiotensinogen in spontaneous hypertension.
Lodwick D; Kaiser MA; Harris J; Cumin F; Vincent M; Samani NJ
Hypertension; 1995 Jun; 25(6):1245-51. PubMed ID: 7768569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
